Compare STRIDES PHARMA SCIENCE with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs BIOCON - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE BIOCON STRIDES PHARMA SCIENCE/
BIOCON
 
P/E (TTM) x 14.5 19.4 74.9% View Chart
P/BV x 0.9 3.0 28.6% View Chart
Dividend Yield % 0.6 0.4 146.7%  

Financials

 STRIDES PHARMA SCIENCE   BIOCON
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
BIOCON
Mar-18
STRIDES PHARMA SCIENCE/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,1471,188 96.5%   
Low Rs642305 210.5%   
Sales per share (Unadj.) Rs317.268.7 461.6%  
Earnings per share (Unadj.) Rs7.87.6 103.9%  
Cash flow per share (Unadj.) Rs25.114.0 179.4%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.20.1 166.9%  
Book value per share (Unadj.) Rs274.386.3 317.6%  
Shares outstanding (eoy) m89.50600.00 14.9%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.810.9 26.0%   
Avg P/E ratio x114.098.9 115.3%  
P/CF ratio (eoy) x35.753.4 66.8%  
Price / Book Value ratio x3.38.6 37.7%  
Dividend payout %25.513.2 192.5%   
Avg Mkt Cap Rs m80,058447,900 17.9%   
No. of employees `0002.56.1 40.8%   
Total wages/salary Rs m4,3419,311 46.6%   
Avg. sales/employee Rs Th11,325.86,705.8 168.9%   
Avg. wages/employee Rs Th1,731.41,514.2 114.3%   
Avg. net profit/employee Rs Th280.1736.9 38.0%   
INCOME DATA
Net Sales Rs m28,39441,234 68.9%  
Other income Rs m9412,062 45.6%   
Total revenues Rs m29,33443,296 67.8%   
Gross profit Rs m3,9658,291 47.8%  
Depreciation Rs m1,5403,851 40.0%   
Interest Rs m1,962615 319.1%   
Profit before tax Rs m1,4035,887 23.8%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m971,569 6.2%   
Profit after tax Rs m7024,531 15.5%  
Gross profit margin %14.020.1 69.5%  
Effective tax rate %6.926.7 26.0%   
Net profit margin %2.511.0 22.5%  
BALANCE SHEET DATA
Current assets Rs m24,83641,486 59.9%   
Current liabilities Rs m18,99321,413 88.7%   
Net working cap to sales %20.648.7 42.3%  
Current ratio x1.31.9 67.5%  
Inventory Days Days7164 111.0%  
Debtors Days Days11394 120.4%  
Net fixed assets Rs m34,28950,661 67.7%   
Share capital Rs m8953,000 29.8%   
"Free" reserves Rs m23,65148,808 48.5%   
Net worth Rs m24,54651,808 47.4%   
Long term debt Rs m15,51317,898 86.7%   
Total assets Rs m65,43799,897 65.5%  
Interest coverage x1.710.6 16.2%   
Debt to equity ratio x0.60.3 182.9%  
Sales to assets ratio x0.40.4 105.1%   
Return on assets %4.15.2 79.0%  
Return on equity %2.98.7 32.7%  
Return on capital %6.99.6 71.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69712,058 130.2%   
Fx outflow Rs m7357,348 10.0%   
Net fx Rs m14,9624,710 317.7%   
CASH FLOW
From Operations Rs m1,8716,621 28.3%  
From Investments Rs m5,826-6,840 -85.2%  
From Financial Activity Rs m-10,157-2,397 423.7%  
Net Cashflow Rs m-2,615-2,612 100.1%  

Share Holding

Indian Promoters % 27.7 40.4 68.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 37.8 8.4 450.0%  
FIIs % 8.6 10.7 80.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 19.9 130.2%  
Shareholders   56,241 109,995 51.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   TTK HEALTHCARE  ALEMBIC LTD  TORRENT PHARMA  AUROBINDO PHARMA  CIPLA  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 18, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS